Cost-effectiveness analysis compares anlotinib plus penpulimab against sorafenib for unresectable hepatocellular carcinoma in China, suggesting better value.
Under the threshold of three times China's per capita GDP, anlotinib plus penpulimab is more cost-effective compared with sorafenib.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: